Paper No. \_\_\_\_ Date Filed: Jan. 14, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

## BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMERIGEN PHARMACEUTICALS LIMITED Petitioner,

v.

JANSSEN ONCOLOGY, INC., Patent Owner.

> Case IPR2016-00286 Patent 8,822,438 B2

## DECLARATION OF BINDU DONOVAN IN SUPPORT OF MOTION TO APPEAR *PRO HAC VICE*

I, Bindu Donovan, declare as follows:

1. I am a partner in the New York Office of Sidley Austin LLP. I have personal knowledge of the facts set forth in this declaration and, if called as a witness, could and would testify competently under oath.

I am a member in good standing of the State Bar of New York (Bar No. 2977981).

3. I have never been suspended or disbarred from practice before any court or administrative body.

4. None of my applications for admission to practice before any court or administrative body have ever been denied.

5. I have not been sanctioned nor have I had a contempt citation imposed on me by any court or administrative body.

6. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trial set forth in part 42 of 37 C.F.R.

7. I acknowledge and agree that I will be subject to the USPTO Rules of Professional Conduct set forth in 37 C.F.R. § 11.101 *et. seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

8. I have not applied to appear *pro hac vice* before the Patent Trial and Appeal Board in the last three years.

## IPR2016-00286 Patent No. 8,822,438 B2

9. I have been a practicing attorney for over 15 years and have been involved in numerous patent cases. I am presently counsel for Patent Owner Janssen Oncology, Inc. in two pending patent litigations<sup>1</sup> involving the patent under review in this proceeding, U.S. Patent No. 8,822,438 (the "'438 patent"). As part of these litigations, I have studied and analyzed the '438 patent and have become very familiar with its subject matter. I have also gained familiarity with certain prior art (including prior art asserted in this IPR proceeding), conception and reduction to practice of the inventions claimed in the '438 patent, and other relevant issues, including claim construction of various claim terms.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on January <u>11</u>, 2016 in New York, New York.

Bindu Donovan

<sup>1</sup> BTG Int'l Ltd., et al. v. Actavis Labs. FL, Inc., et al., C.A. No. 2:15-cv-05909-KM-JBC (D.N.J.) and Janssen Biotech, Inc., et al. v. Mylan Pharm. Inc., et al., C.A. No. 1:15-cv-00130-IMK (N.D. W. Va.). IPR2016-00286 Patent No. 8,822,438 B2

## **CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a copy of the foregoing Declaration of Bindu Donovan in Support of Motion to Appear *Pro Hac Vice* was served on counsel of record on January 14, 2016 by filing this document through the Patent Review Processing System, as well as delivering a copy via electronic mail to counsel of record for the Petitioner at the following addresses:

> William Hare Gabriela Materassi McNeeley Hare & War LLP bill@miplaw.com materassi@miplaw.com

Date: January 14, 2016

DOCKF

RM

Respectfully submitted,

By: <u>/Dianne B. Elderkin/</u> Dianne B. Elderkin Registration No. 28,598 Counsel for Patent Owner